UCB Presents Crohn’s Disease Therapy Evaluation Data For Cimzia at DDW

UCB Presents Crohn’s Disease Therapy Evaluation Data For Cimzia at DDW
Biopharmaceutical company UCB recently presented data on the study of the drug Cimzia for the treatment of Crohn's disease at Digestive Disease Week 2015, which wraps up today in Washington, D.C. Cimzia was approved in the United States in 2008 for the reduction of symptoms associated with Crohn's disease, as well as maintaining clinical responses in adults with a moderate to severely active condition. The treatment is indicated for patients who do not respond to conventional treatment methods and is currently the only Fc-free, PEGylated anti-Tumor Necrosis Factor (TNF) treatment approved for patients with Crohn's disease. "UCB is committed to supporting ongoing research that generates new clinical insights into our immunological treatments," explained Chief Medical Officer and Executive Vice President at UCB, Iris Loew Friedrich. "Research on Cimzia after its initial US approval in 2008 has spanned seven years and these latest results contribute to the body of evidence supporting its important role as a treatment for Crohn's disease." UCB is conducting a PEGylated antibody fragment clinical assessment of the safety and efficacy of Cimzia involving patients with Crohn's disease in a study entitled PRECiSE. The study is among the largest and most comprehensive clinical studies focused on an anti-TNF to treat the disease, and is comprised of two placebo-controlled studies, as well two open-label safety follow-up studies. PRECiSE 1 and 2 were designed to evaluate the FDA-approved treatment, with a primary efficacy endpoint be
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *